BAF Complex Modulating Compounds for BRG1 Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with alterations in BRG1 or BRM proteins, which are components of the BAF complex, are inadequate in modulating the complex's activity effectively.
Innovation Solution
Development of specific compounds, such as those represented by Formula I, which can modulate the activity of BAF complexes by interacting with BRG1 or BRM proteins, thereby treating associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for disorders associated with BRG1 or BRM protein alterations, then treatment coverage is provided, but the effectiveness in modulating BAF complex activity is inadequate
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (Formula I) that alter the interaction parameters between inhibitors and BAF complex components. By modifying chemical parameters such as substituent groups (R1, R2, R3, R4, R5, R6), heteroatoms (X, Y, Z), and linkers (L), the invention achieves effective modulation of BAF complex activity where previous treatments failed.
2Reliability
If specific compounds (Formula I) are developed to modulate BAF complex activity, then therapeutic effectiveness is improved, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecular structure of Formula I into distinct functional segments: heteroaryl/heterocyclyl groups (R1-R6), core structure (X, Y, Z), linker (L), and substituent (B). This segmentation allows for systematic optimization of each component's contribution to BAF complex modulation while maintaining overall therapeutic effectiveness.
Solution Approach 2:
The invention uses parameter changes to manage complexity by establishing defined ranges and options for each molecular parameter (R1-C6-C10 aryl, R2-C2-C9 heteroaryl, X/Y/Z as N or CH, L as alkylene or heteroalkylene). These parameter specifications provide a structured framework that guides compound selection and treatment personalization without creating unmanageable complexity.
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.